The global Preimplantation Genetic Diagnosis Market is estimated to be valued at US$ 64.08 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preimplantation genetic diagnosis (PGD) involves testing embryos before implantation during in-vitro fertilization (IVF) to help identify genetic defects. PGD helps to select embryos without monogenic defects and chromosomal abnormalities. It assists couples with a family history of known genetic diseases to have healthy children by avoiding passing on genetic disorders.
Market key trends:
One of the key trends in the PGD market is the increasing adoption of PGD techniques for aneuploidy screening. Aneuploidy refers to an abnormal number of chromosomes and is a leading cause of miscarriage and birth defects. PGD helps identify chromosomally abnormal embryos and transfer normal embryos to increase the chances of successful implantation and live birth. Another major trend is the development of new techniques like next-generation sequencing (NGS) for comprehensive chromosomal testing in PGD. NGS allows testing of all 24 chromosomes in one go and provides accurate results. Growing public awareness about PGD and the benefits of chromosomal testing is also fueling the demand for PGD procedures globally.
SWOT Analysis
Strength: Preimplantation Genetic Diagnosis allows detection of genetic diseases or chromosomal abnormalities in embryos before implantation, reducing the chances of passing on genetic disorders to offspring. It provides potential parents with information needed to select the healthiest embryos.
Weakness: The process is costly and complex, limiting its access. Ethical issues also surround this technology regarding embryo selection and potential “designer babies”.
Opportunity: Rising infertility rates and increasing awareness about genetic disorders present an opportunity for growth. Advancements in technologies like next-generation sequencing are further improving accuracy and accessibility of PGD.
Threats: Strict regulations in some countries limit the application of PGD. Social and religious objections to the procedure pose challenges. Competition from other assisted reproductive technologies can also threaten market share.
Key Takeaways
The global Preimplantation Genetic Diagnosis Market Growth is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing demand for assisted reproductive technologies and rising awareness about genetic disorders.
Regional analysis: North America dominates the global PGD market currently due to stringent government regulations in support of the procedure and presence of major players. Asia Pacific is expected to witness the fastest growth owing to rising medical tourism, growing disposable incomes, and increasing infertility rates in the region.
Key players operating in the Preimplantation Genetic Diagnosis market are Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation. Prefunding and mergers and acquisitions are key growth strategies adopted by these players to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.